Cash Runway: Expected to extend beyond 2027. 2seventy bio Inc (NASDAQ:TSVT) successfully completed the sale of its oncology and autoimmune R&D pipeline to Regeneron, streamlining operations. The ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today. The company’s ...

We tested home dehumidifiers to find the most efficient picks including the best dehumidifiers for basements, small ...

We've accomplished a tremendous amount to improve this picture. We've successfully completed the sale of our oncology and autoimmune R&D pipeline to Regeneron, including about 160 employees. The ...

"I am thrilled to further strengthen and enrich Ocular's senior leadership team with the appointment of Namrata as Chief ...

The company’s shares closed yesterday at $13.07. Van Buren covers the Healthcare sector, focusing on stocks such as Regeneron, Tectonic Therapeutic, and Gilead Sciences. According to TipRanks, Van ...

Operational realignment remains a pivotal narrative, with the sale of oncology assets to Regeneron providing resources for ...

Bayer AG BAYRY reported third-quarter 2024 core earnings of 7 cents per American Depositary Receipt (ADR), which missed the ...

Collaborations with partners like BioNTech, Regeneron and WuXi Biologics further underscore the platform’s capabilities and its potential to revolutionize cancer treatment. This press release contains ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to improving vision in the real world through ...